Histogenics Corp Downgraded by Zacks to Sell (HSGX)

By Jeff Rose

Zacks cut shares of Histogenics Corp (NASDAQ:HSGX)from a hold rating to a sell rating in a research reportsent to investors on Thursday morning, Market Beatreports.

According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “

Shares of Histogenics Corp (NASDAQ:HSGX) traded down 11.99% during midday trading on Thursday, hitting $5.43. 200 shares of the stock traded hands. The firm has a 50-day moving average price of $6.29 and a 200 day moving average price of $7.93. The stock’s market cap is $71.83 million. Histogenics Corp has a one year low of $5.09 and a one year high of $12.47.


Related Articles

Back to top button